Guillain-Barré Syndrome Presenting as Pseudo-Cerebellar Syndrome: A Case Report from a Resource-Limited Setting in Sub-Saharan Africa Guillain-Barré Syndrome (GBS) is the most frequent cause of acute ...
Designed to reinforce lucerastat as the first oral therapy suitable for all patients with Fabry disease, irrespective of their mutation type. The program is expected to support a potential regulatory ...
TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data highlighting BRIUMVI ® (ublituximab-xiiy), to be presented at the Americas Committee for Treatment and Research in ...
What key experiences or clinical gaps motivated your focus on advancing prostate cancer diagnostics, particularly MRI-led ...
Allschwil, Switzerland - February 06, 2026Idorsia Ltd (SIX: IDIA) announces the design of its FDA-agreed Phase 3 registration program for lucerastat in Fabry disease. Building on the robust biomarker ...
Helping a senior stay hydrated isn't about forced consumption; it's about making the healthy choice the easiest choice. By infusing water with flavor, serving "watery" foods, and setting a gentle ...
Detailed price information for Profound Medical Corp (PRN-T) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results